


Accelerating drug development for lung diseases: New insights from single-cell genomics

December 6 2023, by Luisa Hoffmann



VWA1+/PLVAP+ ectopic ECs appear in alveolar septae of early-stage lung fibrosis. (a) Representative Immunofluorescence images of CLDN5 (green), PLVAP (red) and PDPN (white) expression in histopathological and microCT-staged IPF tissues. Yellow arrowheads indicate ectopic PLVAP+ vessels. White arrowheads mark PDPN+ lymphatics. Scale bars = 200 μm (overview images) and 50 μm (enlarged views). (b) Bar graphs show the quantification of PLVAP signal (percentage of PLVAP+ area to the total area of lung ROIs) in vivo ($n = 5$ control and $n = 4$ IPF patients). Statistics: Unpaired t-test. (c) Example images of quantification methodology of the alveolar PLVAP+ vessel area (normalized to the alveolar septal (AS) length) against the AS thickness. Representative alveolar septae of control and IPF1 tissues are shown. Scale bars = 50 μm . (d) The scatter plot shows the quantitative analysis of 60 AS derived from both control and IPF1 tissues, demonstrating a significant correlation of the normalized PLVAP+ vessel area with AS thickness (Pearson's $r = 0.69$, P

Citation: Accelerating drug development for lung diseases: New insights from single-cell genomics (2023, December 6) retrieved 27 April 2024 from <https://medicalxpress.com/news/2023-12-drug-lung-diseases-insights-single-cell.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.